ASCO GI 2023 Conference Coverage
Playback speed
10 seconds
ASCO GI 2023 Multicenter, Single-Arm, Multi-Cohort, Phase II INFINITY Trial: Tremelimumab & Durvalumab as Neoadjuvant Treatment of Patients With MSI-H Resectable GC/GEJC
By
ASCO GI 2023 Conference Coverage
FEATURING
Filippo Pietrantonio
By
ASCO GI 2023 Conference Coverage
FEATURING
Filippo Pietrantonio
208 views
January 31, 2023
Login to view comments.
Click here to Login
Videos